A Biodegradable Mesh-Covered Drug Eluting Coronary Embolic Protection Stent: A Promising Solution for Embolization Treatment for Coronary Arteries

Minocha Dr. Pramod Kumar, Kothwala Dr. Deveshkumar Mahendralal, Lodha Dikshita Yogendrasinh, Desai Mansi Samir, Kumar AyushInternational Journal Of Medical Science And Clinical Invention 2023 · DOI

TL;DR

This paper introduces a novel biodegradable, drug-eluting coronary stent designed to prevent dangerous embolic events during percutaneous coronary intervention (PCI). Bench-scale testing demonstrates its robust radial strength and the potential of its biodegradable mesh to significantly reduce complications like restenosis and thrombosis, offering a promising advancement in cardiovascular treatment.

What Problem Does This Paper Address?

Percutaneous coronary intervention (PCI), a common procedure to open blocked coronary arteries, carries a significant risk of distal embolization. This occurs when blood clots or plaque fragments break off during the procedure and travel downstream, potentially causing further blockages and damage to the heart muscle. While thrombus aspiration can help, it doesn't eliminate the risk, especially from unstable clots or plaque disruption during stent deployment. Existing solutions often involve separate embolic protection devices, adding complexity. This paper addresses the need for an integrated solution that inherently minimizes distal embolization.

Methods

The researchers developed a "Mesh Covered Drug Eluting Coronary Embolic Protection Stent." The core innovation lies in its construction:

  • Stent Body: A cobalt-chromium L605 laser-slotted hypo-tube, designed for controlled expansion, flexibility, and high radial force. It's coated with sirolimus, a drug known to prevent immune cell activation and antibody formation, thus reducing restenosis and thrombosis.
  • Biodegradable Mesh Covering: A 28-micron Poly Lactic-co-Glycolic Acid (PLGA) polymer filament knitted into a mesh. This mesh acts as a protective barrier, preventing embolic material from escaping. It's designed to be flexible and strong, attaching seamlessly to the stent.
  • Manufacturing Process: The mesh was created using a circular weft knitting machine and then meticulously wrapped around the sirolimus-coated stent using forceps and a needle. A PLGA monofilament was used to secure the mesh ends. The entire assembly was then re-coated with sirolimus to compensate for any drug loss during the mesh application.
  • Crimping: The final stent-catheter assembly was carefully crimped onto a balloon catheter using a specialized machine in a controlled environment to ensure consistency and quality.
  • Testing:
    • Radial Strength Testing: Performed on sterile samples using a calibrated radial analyzer according to EN ISO 225392:2012 standards to assess the stent's ability to withstand forces within the artery.
  • Tensile Strength Testing: Evaluated the PLGA monofilament using a Universal Testing Machine to measure its strength, elongation, modulus, and break load, ensuring its durability as part of the mesh.

Datasets

Not discussed in the paper. The study relies on bench-scale experiments and material testing rather than clinical datasets.

Key Insights and Ideas

  • Integrated Embolic Protection: The most significant insight is the development of a stent that inherently provides embolic protection through its mesh covering, rather than relying on a separate device. This simplifies the procedure and potentially improves patient outcomes.
  • Biodegradable Advantage: The use of a biodegradable PLGA mesh offers a key advantage over traditional permanent materials. It eliminates the need for additional removal procedures and is designed to degrade over time, potentially reducing long-term complications.
  • Dual Action: The combination of the sirolimus drug coating and the physical barrier of the mesh provides a multi-pronged approach to preventing restenosis, thrombosis, and embolization.
  • Robustness Demonstrated: The bench-scale experiments confirm that the stent system possesses high radial strength and the mesh material exhibits sufficient tensile strength, indicating its suitability for the demanding environment of coronary arteries.

Key Results

  • Radial Strength: All tested stent samples surpassed the minimum required universal radial strength of 10 N, with measured values ranging from 34.46 N to 58.85 N. This indicates the stent can withstand significant forces within the coronary arteries.
  • Tensile Strength of PLGA Monofilament: The PLGA monofilament used for the mesh demonstrated good tensile characteristics, with peak stress values around 97,637 psi, elongation up to 48%, and break loads up to 45.488 gf. These properties are crucial for the mesh's integrity and flexibility.
  • Bench-Scale Validation: The study confirmed through bench-scale experiments that the "Mesh Covered Drug Eluting Coronary Embolic Protection Stent" exhibits robust strength and is a potential solution for mitigating distal embolization during PCI.

Limitations and Future Work

  • Limitations: The study is based on bench-scale experiments and material testing. The authors acknowledge that this is a pre-clinical study and the results need to be validated in vivo.
  • Future Work: The authors have commenced a pre-clinical study and anticipate unveiling its results in a forthcoming research article. This suggests the next steps involve animal studies to further assess the stent's performance and safety in a biological context before potential human trials.

Summary updated

Abstract

The newly developed "Mesh Covered Drug Eluting Coronary Embolic Protection Stent" is specifically designed to address the problem of distal embolization during percutaneous coronary intervention (PCI), a common procedure for treating myocardial infarction. This study aimed to evaluate the strength of the mesh component in patients with coronary artery disease. The stent system consists of a cobalt-chromium metal stent covered with a knitted mesh made of biodegradable PLGA polymer, which effectively prevents embolic events. The findings of the study demonstrated that the stent system exhibited high radial strength, withstanding significant levels of deformation before failure. This indicates that the mesh covered drug eluting coronary embolic protection stent has the potential to effectively mitigate distal embolization during PCI. The use of a biodegradable mesh in conjunction with the stent offers advantages over traditional stents by reducing the risk of restenosis, thrombosis, and inflammation, thereby improving long-term outcomes. Through bench-scale experiments, we have verified that the "Mesh Covered Drug Eluting Coronary Embolic Protection Stent" exhibits robust strength, validating its potential as an effective solution for addressing distal embolization during percutaneous coronary intervention.
BibTeX
@article{kumar2023biodegradable,
  author = {Minocha Dr. Pramod Kumar and Kothwala Dr. Deveshkumar Mahendralal and Lodha Dikshita Yogendrasinh and Desai Mansi Samir and Kumar Ayush},
  title = {{A Biodegradable Mesh-Covered Drug Eluting Coronary Embolic Protection Stent: A Promising Solution for Embolization Treatment for Coronary Arteries}},
  journal = {International Journal Of Medical Science And Clinical Invention},
  year = {2023},
  doi = {10.18535/ijmsci/v10i7.06},
}
Figure